Copyright © 1988 by the European Society of Cardiology.
© 1988 The European Society of Cardiology
Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2–7 year follow-up
*Department of Medicine, Karolinska Institutet, Danderyd Hospital, S-182 88 Danderyd Danderyd, Sweden
Department of Mathematics, University of Göteborg S-412 96 Göteborg, Sweden
Department of Statistics, AB Hässle S-431 83 Mölndal, Sweden
Received 5 March 1987; revised 23 September 1987; .
Reprint requests to: Gunnar Olsson, M.D., Department of Medicine, Danderyd Hospital, S-182 88 Danderyd, Sweden
Abstract
In a randomized double-blind postinfarction study 301 patients were treated with either metoprolol 100 mg b.i.d. (n= 154) or placebo (n= 147) for three years. After the three-year treatment period the study preparation was gradually withdrawn over one week, followed by another 2–7 year follow-up. Mortality and morbidity data were studied both during the intervention period (reported elsewhere) and over the period following withdrawal of study therapy.
During the period following the withdrawal of the trial preparation, there were 16 (14%) and 31 (24%) deaths in the previously placebo and metoprolol groups, respectively (P = 0.10). Corresponding figures for reinfarctions and cerebrovascular events were 15 (13%) vs. 12 (9%) and 14 (12%) vs. 9 (7%) (NS). From a Cox regression analysis taking 13 different variables into account, a model describing the risk for subsequent death was constructed. The model identified the following important variables: sex (relative risk (rr) = 2.4), beta-blocker withdrawal (rr = 2.l), performance on exercise test and digitalis treatment (rr = 2.3, P < 0.05).
The present results, as well as those from other studies, seem to favour continuous postinfarction beta blocker therapy provided that there are no severe side-effects from therapy. Digitalis therapy in postinfarction patients in sinus rhythm may have adverse effects on survival during long-term follow-up.
Key Words: Prognosis • beta-blockade • metoprolol • postinfarction • withdrawal
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J., January 1, 2003; 24(1): 28 - 66. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Camm and Y. G. Yap Clinical Trials of Antiarrhythmic Drugs in Postmyocardial Infarction and Congestive Heart Failure Patients Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 99 - 106. [PDF]
|
|
|
|
 |
|
 M. Verstraete, C. R. M. Prentice, M. Samama, and R. Verhaeghe A European View on the North American Fifth Consensus on Antithrombotic Therapy Chest, June 1, 2000; 117(6): 1755 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A D Flapan Fortnightly Review: Management of patients after their first myocardial infarction BMJ, October 29, 1994; 309(6962): 1129 - 1134. [Full Text]
|
|